share_log

艾美疫苗：自願性公告 - 四價MDCK細胞流感病毒疫苗提交臨床試驗預申請

AIM VACCINE: VOLUNTARY ANNOUNCEMENT - PRE-APPLICATION FOR CLINICAL TRIALS FOR QUADRIVALENT INFLUENZA VIRUS VACCINE (MDCK CELLS) SUBMITTED

香港交易所 ·  Mar 27 20:00
Summary by Moomoo AI
艾美疫苗股份有限公司於2024年3月27日向相關監管機構提交了四價MDCK細胞流感病毒疫苗的臨床試驗預申請。該疫苗採用的MDCK細胞培養技術，可取代傳統的雞胚工藝，具有生產週期短、原材料供應穩定、應對病毒突變能力強等優勢。本公司研發的疫苗不含卵清蛋白，降低了過敏風險，並可針對世界衛生組織公佈的每季候選毒株進行生產，更好地滿足公共衛生需求。該疫苗適用於6月齡及以上人群，尤其是易感者及高風險人群。艾美疫苗的這一業務發展為股東及潛在投資者提供了最新信息，並由董事會主席、執行董事兼首席執行官周延先生於2024年3月28日發布。
艾美疫苗股份有限公司於2024年3月27日向相關監管機構提交了四價MDCK細胞流感病毒疫苗的臨床試驗預申請。該疫苗採用的MDCK細胞培養技術，可取代傳統的雞胚工藝，具有生產週期短、原材料供應穩定、應對病毒突變能力強等優勢。本公司研發的疫苗不含卵清蛋白，降低了過敏風險，並可針對世界衛生組織公佈的每季候選毒株進行生產，更好地滿足公共衛生需求。該疫苗適用於6月齡及以上人群，尤其是易感者及高風險人群。艾美疫苗的這一業務發展為股東及潛在投資者提供了最新信息，並由董事會主席、執行董事兼首席執行官周延先生於2024年3月28日發布。
AMIE VACCINES CO., LTD. SUBMITTED A CLINICAL TRIAL PRE-APPLICATION FOR QUADRUPLE MDCK CELLULAR INFLUENZA VIRUS VACCINE TO THE RELEVANT REGULATORY AUTHORITIES ON MARCH 27, 2024. The vaccine, which uses MDCK cell culture technology, replaces traditional embryonic processes, has the advantages of short production cycles, stable raw material supply, and strong resistance to viral mutations. The vaccine developed by the company does not contain egg protein, reduces the risk of allergies and can be produced on the quarterly candidate strains published by the World Health Organization to better meet public health needs. The vaccine is suitable for people aged 6 months and above, especially those who are susceptible and at high risk. This business development for Amey Vaccines provides an update to shareholders and potential investors and was announced by Mr. Zhou Yan, Chairman of the Board, Executive Director and Chief Executive Officer, on March 28, 2024.
AMIE VACCINES CO., LTD. SUBMITTED A CLINICAL TRIAL PRE-APPLICATION FOR QUADRUPLE MDCK CELLULAR INFLUENZA VIRUS VACCINE TO THE RELEVANT REGULATORY AUTHORITIES ON MARCH 27, 2024. The vaccine, which uses MDCK cell culture technology, replaces traditional embryonic processes, has the advantages of short production cycles, stable raw material supply, and strong resistance to viral mutations. The vaccine developed by the company does not contain egg protein, reduces the risk of allergies and can be produced on the quarterly candidate strains published by the World Health Organization to better meet public health needs. The vaccine is suitable for people aged 6 months and above, especially those who are susceptible and at high risk. This business development for Amey Vaccines provides an update to shareholders and potential investors and was announced by Mr. Zhou Yan, Chairman of the Board, Executive Director and Chief Executive Officer, on March 28, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more